# Arjunolic Acid

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/arjunolic-acid
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 4 / 10
**Category:** Compound
**Also Known As:** 2α,3β,23-trihydroxyolean-12-en-28-oic acid, AA, Arjun acid, Terminalia acid, Arjuna triterpene, Pentacyclic triterpenoidal saponin

## Overview

Arjunolic acid is a pentacyclic triterpenoid compound derived from Terminalia arjuna bark that provides [cardiovascular](/ingredients/condition/heart-health) and [neuroprotective effect](/ingredients/condition/cognitive)s. It works primarily through PPARα activation and anti-[inflammatory pathway](/ingredients/condition/inflammation)s to protect heart and brain tissue.

## Health Benefits

• [Cardiovascular](/ingredients/condition/heart-health) protection: Reduced cardiac hypertrophy markers and improved heart function (38.53% to 46.67% fractional shortening) in animal models through PPARα activation
• Neuroprotection: Decreased brain infarct size and neurological deficits in rat stroke models at 10-20 mg/kg doses
• Anti-cancer activity: Reduced breast cancer tumor burden by ~89% in DMBA-induced rat models, comparable to tamoxifen
• Anti-depressive effects: Ameliorated depressive behaviors and increased [BDNF](/ingredients/condition/cognitive)/5-HT levels in LPS-induced mouse models
• [Anti-inflammatory](/ingredients/condition/inflammation) action: Shifted microglial phenotype to M2 and modulated cytokines (reduced TNF-α, IL-6; increased IL-10) in preclinical studies

## Mechanism of Action

Arjunolic acid activates peroxisome proliferator-activated receptor alpha (PPARα), which regulates fatty acid oxidation and reduces cardiac hypertrophy markers. The compound also inhibits [pro-inflammatory cytokine](/ingredients/condition/inflammation)s and reduces [oxidative stress](/ingredients/condition/antioxidant) through modulation of nuclear factor-kappa B (NF-κB) signaling. Additionally, it enhances [mitochondrial function](/ingredients/condition/energy) and supports cellular energy [metabolism](/ingredients/condition/weight-management) in cardiac and neural tissues.

## Clinical Summary

Research on arjunolic acid is primarily limited to animal studies with promising [cardiovascular](/ingredients/condition/heart-health) results. Rat models demonstrated 38.53% to 46.67% fractional shortening improvement in heart function and reduced cardiac hypertrophy markers through PPARα activation. Stroke studies in rats showed decreased brain infarct size and improved neurological outcomes at 10-20 mg/kg doses. Human clinical trials are currently lacking, making evidence strength preliminary despite encouraging preclinical data.

## Nutritional Profile

Arjunolic Acid is a pure triterpenoid saponin compound (C30H48O5, molecular weight ~496.7 g/mol), not a whole food ingredient, so classical macronutrient/micronutrient profiling does not apply. Key bioactive profile: Primary constituent is the pentacyclic triterpenoid scaffold with three hydroxyl groups (-OH) at C-2α, C-3β, and C-23 positions, and a carboxylic acid group at C-28, conferring amphiphilic properties. Isolated predominantly from the bark of Terminalia arjuna at concentrations of approximately 0.1–0.5% dry weight of bark extract. Bioactive concentration thresholds established in preclinical models: 10–20 mg/kg body weight (oral/intraperitoneal) for [neuroprotective](/ingredients/condition/cognitive) and cardioprotective effects; ~50 mg/kg for anti-tumor activity in rodent models. No caloric, protein, fat, fiber, vitamin, or mineral content is applicable as it is an isolated phytochemical. Bioavailability: Oral bioavailability is considered moderate-to-low due to its high molecular weight and polarity; first-pass hepatic [metabolism](/ingredients/condition/weight-management) is likely significant. Lipophilicity (estimated LogP ~2.8–3.5) suggests partial passive diffusion across lipid membranes. Nanoformulation and phospholipid complexation have been explored to enhance bioavailability. PPARα agonist activity confirmed at molecular level, supporting its metabolic and cardioprotective mechanism of action.

## Dosage & Preparation

Preclinical studies used: 10-20 mg/kg orally for 7 days (neuroprotection), 1 mg/kg for 121 days (cancer), with doses determined by response curves in cardiac models. No human dosage data or standardized extract preparations are available. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Safety data for arjunolic acid is limited due to lack of human clinical trials. Animal studies at therapeutic doses (10-20 mg/kg) showed no significant adverse effects, but long-term safety remains unknown. Potential interactions with [cardiovascular](/ingredients/condition/heart-health) medications and PPARα agonists like fibrates should be considered due to overlapping mechanisms. Pregnant and breastfeeding women should avoid use due to insufficient safety data.

## Scientific Research

Current evidence for arjunolic acid is limited to preclinical animal and cellular studies, with no human clinical trials, RCTs, or meta-analyses identified. Key animal studies include cardiac hypertrophy models in rats, focal cerebral ischemia-reperfusion studies (n=8-10 per group), and a 121-day breast cancer study in DMBA-induced rats showing 89% tumor reduction at 1 mg/kg dosing.

## Historical & Cultural Context

Arjunolic acid from Terminalia arjuna bark has been central to Ayurvedic cardioprotective remedies for centuries, traditionally used for preventing myocardial necrosis and supporting heart health. The compound is also found in Akebia trifoliata fruits, which are used in Traditional Chinese Medicine for psychiatric disorders.

## Synergistic Combinations

Terminalia arjuna extract, CoQ10, Resveratrol, Curcumin, Quercetin

## Frequently Asked Questions

### What is the effective dosage of arjunolic acid?

Animal studies used 10-20 mg/kg doses for neuroprotection and cardiovascular benefits. Human dosage recommendations are not established due to lack of clinical trials, making professional consultation essential before use.

### How does arjunolic acid help heart health?

Arjunolic acid activates PPARα receptors to improve cardiac function, achieving 38.53-46.67% fractional shortening in animal studies. It reduces cardiac hypertrophy markers and enhances fatty acid oxidation in heart muscle cells.

### Can arjunolic acid prevent stroke damage?

Rat studies show arjunolic acid at 10-20 mg/kg doses reduced brain infarct size and improved neurological deficits after stroke. However, human stroke prevention or treatment effects remain unproven without clinical trials.

### What are the side effects of arjunolic acid?

No significant adverse effects were reported in animal studies at therapeutic doses. However, human side effects are unknown due to lack of clinical research, requiring caution and medical supervision for use.

### Is arjunolic acid the same as Terminalia arjuna extract?

Arjunolic acid is a specific pentacyclic triterpenoid compound found in Terminalia arjuna bark extract. The whole extract contains multiple compounds including arjunic acid and arjungenin, while arjunolic acid is one isolated bioactive component.

### What is the research quality and evidence strength for arjunolic acid's anti-cancer benefits?

Preclinical studies in DMBA-induced rat breast cancer models demonstrate that arjunolic acid reduced tumor burden by approximately 89%, showing effects comparable to standard cancer interventions. However, current evidence is limited to animal models, and human clinical trials are needed to establish efficacy and safety in cancer prevention or treatment. The anti-cancer mechanism appears linked to apoptosis induction and tumor growth suppression pathways.

### Who should consider arjunolic acid supplementation and who should avoid it?

Arjunolic acid may benefit individuals with cardiovascular concerns, mild cardiac dysfunction, or those at risk for stroke, particularly those with PPARα-related metabolic issues. It should be avoided by pregnant or nursing women due to insufficient safety data, and those taking anticoagulant or antiplatelet medications should consult a healthcare provider before use. Individuals with kidney or liver disease should also seek medical guidance before supplementation.

### Does arjunolic acid interact with common cardiovascular or blood pressure medications?

Arjunolic acid activates PPARα pathways and may potentiate effects of certain cardiovascular medications, particularly lipid-modifying drugs and blood pressure regulators. Co-administration with anticoagulants or antiplatelet agents may require monitoring due to potential additive effects on hemostasis. Direct drug interaction studies are limited, making consultation with a healthcare provider essential before combining with prescription cardiovascular medications.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*